|
1
|
Sawai H, Nishida N, Khor SS, Honda M,
Sugiyama M, Baba N, Yamada K, Sawada N, Tsugane S, Koike K, et al:
Genome-wide association study identified new susceptible genetic
variants in HLA class I region for hepatitis B virus-related
hepatocellular carcinoma. Sci Rep. 8:79582018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chu CM: Natural history of chronic
hepatitis B virus infection in adults with emphasis on the
occurrence of cirrhosis and hepatocellular carcinoma. J
Gastroenterol Hepatol. 15 (Suppl):E25–E30. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Henderson S and Fenton T: APOBEC3 genes:
Retroviral restriction factors to cancer drivers. Trends Mol Med.
21:274–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Teng B, Burant CF and Davidson NO:
Molecular cloning of an apolipoprotein B messenger RNA editing
protein. Science. 260:1816–1819. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swanton C, McGranahan N, Starrett GJ and
Harris RS: APOBEC enzymes: Mutagenic fuel for cancer evolution and
heterogeneity. Cancer Discov. 5:704–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doehle BP, Schafer A and Cullen BR: Human
APOBEC3B is a potent inhibitor of HIV-1 infectivity and is
resistant to HIV-1 Vif. Virology. 339:281–288. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prasetyo AA, Sariyatun R, Revion o, Sari
Y, Hudiyon o, Haryati S, Adnan ZA, Harton o and Kageyama S: The
APOBEC3B deletion polymorphism is associated with prevalence of
hepatitis B virus, hepatitis C virus, Torque Teno virus, and
Toxoplasma gondii co-infection among HIV-infected individuals. J
Clin Virol. 70:67–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berger G, Durand S, Fargier G, Nguyen XN,
Cordeil S, Bouaziz S, Muriaux D, Darlix JL and Cimarelli A:
APOBEC3A is a specific inhibitor of the early phases of HIV-1
infection in myeloid cells. PLoS Pathog. 7:e10022212011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakaya Y, Stavrou S, Blouch K, Tattersall
P and Ross SR: In vivo examination of mouse APOBEC3- and human
APOBEC3A- and APOBEC3G-mediated restriction of parvovirus and
herpesvirus infection in mouse models. J Virol. 90:8005–8012. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Minkah N, Chavez K, Shah P, Maccarthy T,
Chen H, Landau N and Krug LT: Host restriction of murine
gammaherpesvirus 68 replication by human APOBEC3 cytidine
deaminases but not murine APOBEC3. Virology. 454-455:215–226. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Henry M, Guetard D, Suspene R, Rusniok C,
Wain-Hobson S and Vartanian JP: Genetic editing of HBV DNA by
monodomain human APOBEC3 cytidine deaminases and the recombinant
nature of APOBEC3G. PLoS One. 4:e42772009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Warren CJ, Xu T, Guo K, Griffin LM,
Westrich JA, Lee D, Lambert PF, Santiago ML and Pyeon D: APOBEC3A
functions as a restriction factor of human papillomavirus. J Virol.
89:688–702. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
OhAinle M, Kerns JA, Li MM, Malik HS and
Emerman M: Antiretroelement activity of APOBEC3H was lost twice in
recent human evolution. Cell Host Microbe. 4:249–259. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gansmo LB, Romundstad P, Hveem K, Vatten
L, Nik-Zainal S, Lønning PE and Knappskog S: APOBEC3A/B deletion
polymorphism and cancer risk. Carcinogenesis. 39:118–124. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xuan D, Li G, Cai Q, Deming-Halverson S,
Shrubsole MJ, Shu XO, Kelley MC, Zheng W and Long J: APOBEC3
deletion polymorphism is associated with breast cancer risk among
women of European ancestry. Carcinogenesis. 34:2240–2243. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Long J, Delahanty RJ, Li G, Gao YT, Lu W,
Cai Q, Xiang YB, Li C, Ji BT, Zheng Y, et al: A common deletion in
the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst.
105:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rezaei M, Hashemi M, Hashemi SM, Mashhadi
MA and Taheri M: APOBEC3 deletion is associated with breast cancer
risk in a sample of southeast iranian population. Int J Mol Cell
Med. 4:103–108. 2015.PubMed/NCBI
|
|
19
|
Gohler S, Da Silva Filho MI, Johansson R,
Enquist-Olsson K, Henriksson R, Hemminki K, Lenner P and Försti A:
Impact of functional germline variants and a deletion polymorphism
in APOBEC3A and APOBEC3B on breast cancer risk and survival in a
Swedish study population. J Cancer Res Clin Oncol. 142:273–276.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marouf C, Gohler S, Filho MI, Hajji O,
Hemminki K, Nadifi S and Försti A: Analysis of functional germline
variants in APOBEC3 and driver genes on breast cancer risk in
Moroccan study population. BMC Cancer. 16:1652016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klonowska K, Kluzniak W, Rusak B,
Jakubowska A, Ratajska M, Krawczynska N, Vasilevska D, Czubak K,
Wojciechowska M, Cybulski C, et al: The 30 kb deletion in the
APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and
creates a transcriptionally active hybrid gene but does not
associate with breast cancer in the European population.
Oncotarget. 8:76357–76374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu M, Wang Y, Wang C, Shen W, Liu J, Geng
L, Cheng Y, Dai J, Jin G, Ma H, et al: The eQTL-missense
polymorphisms of APOBEC3H are associated with lung cancer risk in a
Han Chinese population. Sci Rep. 5:149692015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He XT, Xu HQ, Wang XM, He XS, Niu JQ and
Gao PJ: Association between polymorphisms of the APOBEC3G gene and
chronic hepatitis B viral infection and hepatitis B virus-related
hepatocellular carcinoma. World J Gastroenterol. 23:232–241. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pons F, Varela M and Llovet JM: Staging
systems in hepatocellular carcinoma. HPB (Oxford). 7:35–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cholongitas E, Papatheodoridis GV, Vangeli
M, Terreni N, Patch D and Burroughs AK: Systematic review: The
model for end-stage liver disease-should it replace Child-Pugh's
classification for assessing prognosis in cirrhosis? Aliment
Pharmacol Ther. 22:1079–1089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Selby LK, Tay RX, Woon WW, Low JK, Bei W,
Shelat VG, Pang TC and Junnarkar SP: Validity of the barcelona
clinic liver cancer and hong kong liver cancer staging systems for
hepatocellular carcinoma in singapore. J Hepatobiliary Pancreat
Sci. 24:143–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dohi H, Ishizuka M, Minoshima S and
Shimizu N: GeneView: Multi-language human gene mapping library with
a graphical user interface. Comput Appl Biosci. 9:459–464.
1993.PubMed/NCBI
|
|
28
|
Dudbridge F: Likelihood-based association
analysis for nuclear families and unrelated subjects with missing
genotype data. Hum Hered. 66:87–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cougot D, Neuveut C and Buendia MA: HBV
induced carcinogenesis. J Clin Virol. 34 (Suppl 1):S75–S78. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kock J and Blum HE: Hypermutation of
hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen
Virol. 89:1184–1191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suspene R, Guetard D, Henry M, Sommer P,
Wain-Hobson S and Vartanian JP: Extensive editing of both hepatitis
B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in
vivo. Proc Natl Acad Sci USA. 102:8321–8326. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiu YL and Greene WC: The APOBEC3
cytidine deaminases: An innate defensive network opposing exogenous
retroviruses and endogenous retroelements. Annu Rev Immunol.
26:317–353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lucifora J, Xia Y, Reisinger F, Zhang K,
Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz
T, et al: Specific and nonhepatotoxic degradation of nuclear
hepatitis B virus cccDNA. Science. 343:1221–1228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roberts SA, Lawrence MS, Klimczak LJ,
Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL,
Saksena G, et al: An APOBEC cytidine deaminase mutagenesis pattern
is widespread in human cancers. Nat Genet. 45:970–976. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burns MB, Temiz NA and Harris RS: Evidence
for APOBEC3B mutagenesis in multiple human cancers. Nat Genet.
45:977–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu R, Zhang X, Zhang W, Fang Y, Zheng S
and Yu XF: Association of human APOBEC3 cytidine deaminases with
the generation of hepatitis virus B × antigen mutants and
hepatocellular carcinoma. Hepatology. 46:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang T, Cai J, Chang J, Yu D, Wu C, Yan
T, Zhai K, Bi X, Zhao H, Xu J, et al: Evidence of associations of
APOBEC3B gene deletion with susceptibility to persistent HBV
infection and hepatocellular carcinoma. Hum Mol Genet.
22:1262–1269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He X, Li J, Wu J, Zhang M and Gao P:
Associations between activation-induced cytidine
deaminase/apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like cytidine deaminase expression, hepatitis B virus
(HBV) replication and HBV-associated liver disease (Review). Mol
Med Rep. 12:6405–6414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chan K, Roberts SA, Klimczak LJ, Sterling
JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski
PA, et al: An APOBEC3A hypermutation signature is distinguishable
from the signature of background mutagenesis by APOBEC3B in human
cancers. Nat Genet. 47:1067–1072. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Caval V, Suspene R, Shapira M, Vartanian
JP and Wain-Hobson S: A prevalent cancer susceptibility APOBEC3A
hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA
damage. Nat Commun. 5:51292014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gerlich WH: Medical virology of hepatitis
B: How it began and where we are now. Virol J. 10:2392013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hyams KC: Risks of chronicity following
acute hepatitis B virus infection: A review. Clin Infect Dis.
20:992–1000. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
McMahon BJ, Alward WL, Hall DB, Heyward
WL, Bender TR, Francis DP and Maynard JE: Acute hepatitis B virus
infection: Relation of age to the clinical expression of disease
and subsequent development of the carrier state. J Infect Dis.
151:599–603. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ott JJ, Stevens GA, Groeger J and Wiersma
ST: Global epidemiology of hepatitis B virus infection: New
estimates of age-specific HBsAg seroprevalence and endemicity.
Vaccine. 30:2212–2219. 2012. View Article : Google Scholar : PubMed/NCBI
|
